Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of V114 versus Prevnar 13 in infants
2018-001151-12Phase 3
- Sponsor
- Merck & Co.
- Start
- Nov 2018
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pneumococcal 15-valent conjugate vaccine, Prevnar 13, hepatitis b vaccine recombinant and rotavirus vaccine, live, oral, pentavalent in pneumococcal disease (5 arms), sponsored by Merck & Co. Primary endpoints: Proportion of participants with adverse events and Immunogenicity.
02
Drugs
pneumococcal 15-valent conjugate vaccinePrevnar 13hepatitis b vaccine recombinantrotavirus vaccine, live, oral, pentavalent
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on 2018-001151-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001151-12.